Urticaria News and Research

RSS
Urticaria are itchy, raised red areas on the skin. Urticaria are caused by a reaction to certain foods, drugs, infections, or emotional stress. Also called hives.
Patients with inducible urticaria can benefit from treatment with asthma drug

Patients with inducible urticaria can benefit from treatment with asthma drug

‘The Agony of Hives’: WAO to offer complementary live webinar on chronic urticaria

‘The Agony of Hives’: WAO to offer complementary live webinar on chronic urticaria

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Contact dermatitis or contact eczema?

Contact dermatitis or contact eczema?

Penicillin allergy testing: an interview with Dr. Eric Macy

Penicillin allergy testing: an interview with Dr. Eric Macy

TARGET My Hives app for people impacted by chronic urticaria now available in Android, iOS systems

TARGET My Hives app for people impacted by chronic urticaria now available in Android, iOS systems

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

NIH researchers identify genetic mutation responsible for vibratory urticaria

NIH researchers identify genetic mutation responsible for vibratory urticaria

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

American Academy of Dermatology releases Chronic Hives Patient App

American Academy of Dermatology releases Chronic Hives Patient App

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting